Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Biosimilars Business Roundup: August 2024

August 31st 2024

By Skylar Jeremias

Article

With the end of the second quarter comes expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.

The Top 5 Biosimilar Articles for the Week of August 26

August 30th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 26, 2024.

Prioritizing Patient-Centered Care in PsA: Key Insights From the 2023 EULAR Guidelines

August 29th 2024

By Skylar Jeremias

Article

The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care.

The Economic Impact of Etanercept Biosimilar Remonopolization in Poland

August 28th 2024

By Skylar Jeremias

Article

Market remonopolization by a biosimilar drug in Poland led to significant price increases for etanercept, resulting in over €3.42 million in excess health care costs, according to a recent study.

Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024

August 27th 2024

By Skylar Jeremias

Article

Sandoz’ earnings report for the first half of 2024 revealed 29% growth in biosimilar revenue, as well as a 7% increase in net sales, showcasing the value of biosimilars for biopharmaceutical manufacturers.

BioRationality: FDA Opens Up Biosimilar Inquiries on Reddit

August 26th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, urges stakeholders to engage with the FDA on its Reddit forum—where a representative will answer complex biosimilar questions—encourages clearing misconceptions, and advocates for updates to the Biologics Price Competition and Innovation Act guidelines.

Strategies for Effective Biosimilar Education, Adoption

August 25th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, suggests implementing targeted educational strategies to overcome physician hesitancy towards biosimilar adoption.

Targeted Incentives Prove Effective in Boosting Adalimumab Biosimilar Uptake in France

August 24th 2024

By Deana Ferreri, PhD

Article

A study comparing 2 different financial incentive programs in France to encourage adalimumab biosimilar use concluded that incentivizing individual clinical units was more effective than incentivizing entire hospitals.

The Top 5 Biosimilar Articles for the Week of August 19

August 23rd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 19, 2024.

Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024

August 22nd 2024

By Skylar Jeremias

Article

Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.